Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan

Area of Science:

• Pharmacovigilance
• Infectious Disease Epidemiology
• Neuroscience

Background:

• Reports of oseltamivir causing abnormal behaviors and increased injury/death risk primarily originated from Japan.
• Japan consumes over 75% of the global oseltamivir supply.
• A 2007 Japanese government warning against oseltamivir use in teenagers remains despite conflicting evidence.

Purpose of the Study:

• To analyze the background of the oseltamivir "ado" in Japan.
• To evaluate the evidence linking oseltamivir to adverse events in influenza patients.
• To explain Japan's difficulty in producing conclusive evidence regarding oseltamivir's safety.

Main Methods:

• Compilation and analysis of diverse information sources, including those not widely available internationally.
• Review of existing evidence on oseltamivir's association with abnormal behaviors.
• Assessment of the diagnostic criteria for influenza-like delirium.

Main Results:

• Accumulating evidence suggests abnormal behaviors are symptoms of influenza-like delirium, not solely attributable to oseltamivir.
• Japan's unique consumption patterns and data collection may hinder definitive conclusions.
• Potential risks of sudden death associated with oseltamivir warrant further investigation.

Conclusions:

• The persistence of the Japanese warning may be disproportionate to the current evidence.
• Distinguishing drug-induced effects from underlying disease symptoms is crucial for accurate pharmacovigilance.
• Further research is needed to clarify the risks and inform future public health policies on oseltamivir.